Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27979642 | 0.93 | HTT (0.89) | RAB9ANPC1HTTTSHRSMN1; SMN2 | |
| SCHEMBL20236314 | 0.87 | HTT (0.80) | RAB9ANPC1HTTTSHRSMN1; SMN2 | |
| SCHEMBL20237168 | 0.87 | HTT (0.80) | RAB9ANPC1HTTTSHRSMN1; SMN2 | |
| SCHEMBL20236298 | 0.86 | HTT (0.78) | RAB9ANPC1HTTTSHRSMN1; SMN2 | |
| SCHEMBL5426206 | 0.86 | HTT (0.78) | RAB9ANPC1HTTTSHRSMN1; SMN2 | |
| SCHEMBL2399513 | 0.86 | HTT (0.78) | RAB9ANPC1HTTTSHRSMN1; SMN2 | |
| SCHEMBL22217863 | 0.85 | HTT (0.76) | RAB9ANPC1HTTTSHRSMN1; SMN2 | |
| SCHEMBL20236816 | 0.84 | HTT (0.74) | RAB9ANPC1HTTTSHRSMN1; SMN2 | |
| SCHEMBL20236931 | 0.84 | HTT (0.74) | RAB9ANPC1HTTTSHRSMN1; SMN2 | |
| SCHEMBL6394132 | 0.83 | HTT (0.72) | RAB9ANPC1HTTTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | RAB9A 3958/4885NPC1 2626/4885HTT 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.